13 completed, 4 recruiting, 4 terminated, 2 unknown. 26 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 13, Recruiting 4, Terminated 4, Unknown 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 1 | 6 | Completed 4, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Dermatofibrosarcoma: new trials by email Literature Review of Dermatofibrosarcoma trials Research Report on Dermatofibrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans Toripalimab, Anlotinib, Standard Chemotherapy - Dermatofibrosarcoma Protuberans (DFSP) | Phase 2 | Not yet recruiting | Yanjie Zhang, MD | 20 | 2026-06-15 | 2026-06-16 |
| Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. Definitive radiotherapy - Soft Tissue Sarcoma (STS), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2026-01-26 | 2026-01-28 |
| Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma preoperative, Quality of life, Functional outcome - Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult | Phase 2 | Recruiting | Oslo University Hospital | 110 | 2026-01-26 | 2026-01-28 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Gemcitabine, 9-ING-41, Docetaxel - Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Withdrawn | Brown University | 2022-03-01 | 2021-12-07 | |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma Ontorpacept (TTI-621), Doxorubicin - Leiomyosarcoma | Phase 2 | Terminated | Pfizer | 76 | 2021-06-22 | 2024-12-11 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin - Sarcoma, Myxofibrosarcoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-04-01 | 2026-04-23 |
| CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma CAB-AXL-ADC, PD-1 inhibitor - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 1 / Phase 2 | Completed | BioAtla, Inc. | 245 | 2018-02-15 | 2025-09-23 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 151 | 2015-11-30 | 2022-08-23 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 72 | 2012-08-22 | 2017-11-30 |
| Phase II Pazopanib Study in Advanced Dermatofibrosarcomas Pazopanib - Dermatofibrosarcomas of DARIER FERRAND(DFSP) | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 23 | 2010-07-01 | 2016-07-01 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma gene expression analysis, polymerase chain reaction, western blotting - Sarcoma | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2008-07-01 | 2014-07-11 |
| AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2008-02-01 | 2018-06-29 |
Showing 20 of 26. Sign in to see all of them.
Sarcoma (18) · Histiocytoma, Malignant Fibrous (16) · Leiomyosarcoma (15) · Liposarcoma (14) · Sarcoma, Synovial (12) · Fibrosarcoma (10) · Neurofibrosarcoma (10) · Hemangiosarcoma (8) · Rhabdomyosarcoma (7) · Osteosarcoma (6) · Chondrosarcoma, Extraskeletal Myxoid (5) · Sarcoma, Alveolar Soft Part (5) · Malignant mesenchymal tumor (4) · Bone Neoplasms (3)
Neoplasms by Histologic Type (26) · Neoplasms, Connective Tissue (26) · Neoplasms, Connective and Soft Tissue (26) · Neoplasms, Fibrous Tissue (26) · Neoplasms (24) · Neoplasms, Muscle Tissue (18) · Fibrosarcoma (16) · Histiocytoma (16) · Neoplasms, Adipose Tissue (13) · Neoplasms, Nerve Tissue (11) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Neurofibroma (10) · Neuromuscular Diseases (10) · Peripheral Nervous System Diseases (10)
Imatinib Mesylate (5) · Doxorubicin (4) · pazopanib (4) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (2) · Docetaxel (2) · Gemcitabine (2) · Ifosfamide (2) · 130-nm albumin-bound paclitaxel (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Albumin-Bound Paclitaxel (1) · Blotting, Western (1) · Dactinomycin (1) · Dexrazoxane (1) · Gene Expression Profiling (1) · HhAntag691 (1)
National Cancer Institute (NCI) (6) · Brown University (2) · Memorial Sloan Kettering Cancer Center (2) · Novartis Pharmaceuticals (2) · Oslo University Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · BioAtla, Inc. (1) · Celgene (1) · City of Hope Medical Center (1) · Dermatologic Cooperative Oncology Group (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Pfizer (1) · Sarcoma Alliance for Research through Collaboration (1) · St. Jude Children's Research Hospital (1) · Tracon Pharmaceuticals Inc. (1)
United States (18) · Canada (3) · France (2) · Norway (2) · United Kingdom (2) · Australia (1) · Germany (1) · Hong Kong (1) · Italy (1) · Poland (1) · Puerto Rico (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Ivar Hompland, MD, PhD (2) · Kjetil Boye, MD, PhD (2) · Aaron R Weiss (1) · Bradley D DeNardo, MD (1) · Bradley DeNardo, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Charles Theuer, MD, PhD (1) · Dirk Schadendorf, MD (1) · Don S Dizon, MD (1) · Edmund Bartlett, MD (1) · Galina G Lagos, MD (1) · Ileana Elias, M.D. (1) · Jessica Gartrell, MD (1) · Margaret von Mehren (1)
PMID 19451429, PMID 19451433, PMID 27502708, PMID 31401903, PMID 32554315, PMID 32702309, PMID 32827353, PMID 32956651, PMID 34515544, PMID 34722269, PMID 37523624, PMID 38579194, PMID 42194972
P30CA008748 (2), U10CA180821 (2), 2009 (1), N01CM62203 (1), N01CM62206 (1), P30CA033572 (1), U01CA069856 (1), U10CA031946 (1), U10CA032102 (1), U10CA098543 (1), U10CA180830 (1), U10CA180886 (1)